HCC

Half of all patients with hepatocellular carcinoma treated with the combination of regorafenib and nivolumab following progression on 2 lines of chemotherapy achieved disease control, according to initial results from a phase 2 proof-of-concept trial.

In a single-arm study, 100% of patients treated with sintilimab plus stereotactic body radiotherapy who had oligometastases of hepatocellular carcinoma achieved disease control and were alive and progression free at 6 months.

The FDA has approved TheraSphere yttrium-90 glass microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

In an interview with Targeted Oncology, Laura Goff, MD, discussed the treatment of hepatocellular carcinoma in the frontline and beyond.

Richard Finn, MD, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib in patients with unrespectable hepatocellular carcinoma.

As part of the virtual 17th Annual Meeting of the International School of Gastrointestinal Oncology, a debate ensued around whether liver-directed or systemic therapy is best for the treatment of patients with HCC.

Ruth He, MD, grants advice on how to treat patients with unresectable hepatocellular carcinoma.

Ruth He, MD, discusses potential options for physicians in their treatment of unresectable hepatocellular carcinoma.

Preliminary data showing the neoadjuvant use of cabozantinib and nivolumab to be feasible for borderline resectable patients with hepatocellular carcinoma that can lead to potentially curative resection.

Good responses to lenvatinib were observed in patients with hepatocellular carcinoma who maintained a high relative dose intensity of 75% or greater.

Although lenvatinib has shown antitumor effects in hepatocellular carcinoma, long-term safety data are lacking.

The FDA has granted an Orphan Drug Designation to the novel small molecule chemotherapeutic uttroside-B for the treatment of patients with hepatocellular carcinoma.

Pembrolizumab monotherapy demonstrated durable antitumor activity and encouraging effects on survival in an evaluation of patients with previously untreated hepatocellular carcinoma.

In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.

Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

In a retrospective, real-world analysis of patients with unresectable hepatocellular carcinoma in the United States, investigators observed that lenvatinib alone was effective as first-line treatment.